March 10, 2022

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has designated the Stanford Health Care Nuclear Medicine and Molecular Imaging Clinic as one of it's first Radiopharmaceutical Therapy Centers of Excellence. 

The SNMMI announcement states, "The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence. The institutions are designated as comprehensive centers that administer multiple radiopharmaceutical therapies—such as those to treat thyroid cancer, prostate cancer and neuroendocrine tumors—and actively engage in radiopharmaceutical therapy research.

SNMMI created the Radiopharmaceutical Therapy Center of Excellence program to certify sites that meet strict regulatory, training, qualification, experience and performance criteria for radiopharmaceutical therapy. With the Radiopharmaceutical Therapy Centers of Excellence designation, institutions can assure patients, their families, referring physicians and payors that rigorous procedures are in place and followed, ultimately leading to appropriate patient selection and optimal outcomes from radiopharmaceutical therapy. "

Andrei Iagaru, MD, Division Chief of Nuclear Medicine and Molecular Imaging, acknowledged the designation, "We are honored to receive this designation in recognition of our decade-long investments in space, equipment, and personnel done to provide advanced theranostic care to our patients."